Centaurus Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Centaurus Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,105	Closed	-$107K	–	761
2023 Q1	$107K	Sell	1,105 -100	-8%	-$10.4K	0.01%	832
2022 Q4	$125K	Sell	1,205 -122	-9%	-$11.5K	0.01%	720
2022 Q3	$112K	Buy	+1,327	New	+$118K	0.01%	773
2022 Q1	–	Sell	-1,205	Closed	-$106K	–	899
2021 Q4	$106K	Buy	+1,205	New	+$99.4K	0.01%	886
2020 Q1	–	Sell	-1,430	Closed	-$121K	–	532
2019 Q4	$121K	Buy	+1,430	New	+$108K	0.02%	569
2019 Q3	–	Sell	-1,530	Closed	-$131K	–	463
2019 Q2	$131K	Buy	+1,530	New	+$131K	0.02%	514
2018 Q3	–	Sell	-631	Closed	-$59K	–	708
2018 Q2	$59K	Buy	+631	New	+$55.3K	0.01%	882

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Centaurus Financial's BMRN Position: Q2 2023 in Review

Centaurus Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 1,105 shares — an estimated $107K sold.

Centaurus Financial first reported a position in BMRN in Q2 2018 and held it in 7 quarters. The position peaked at $131K in Q2 2019. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Centaurus Financial reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Centaurus Financial sold 1,105 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $107K.
Centaurus Financial first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Centaurus Financial's BioMarin Pharmaceuticals position peaked at $131K in Q2 2019.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Centaurus Financial's 13F filing for Q2 2023, filed 15 Aug 2023.